Zobrazeno 1 - 10 of 23 pro vyhledávání: '"Anne, North"'
1
Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione
Autor: Theresa Sullivan, Laurence Corash, Nina Mufti, Anne North
Publikováno v: Transfusion
BACKGROUND The nucleic acid targeted pathogen reduction (PR) system utilizing amustaline (S‐303) and glutathione (GSH) is designed to inactivate blood‐borne pathogens and leukocytes in red blood cell concentrates (PR‐RBCC). Inactivation is atta
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36dcb2dec72b763023c14705d7c10c4c
http://europepmc.org/articles/PMC7027779
Zobrazit plný text záznamu
3
Amustaline‐glutathione pathogen‐reduced red blood cell concentrates for transfusion‐dependent thalassaemia
Autor: Katie Waldhaus, Raffaella Origa, Laurence Corash, Jin-Sying Lin, Anne North, Anna Erickson, Richard J. Benjamin, Norman Huang, Yesim Aydinok, Nina Mufti, Christine Ernst, Antonio Piga
Publikováno v: British Journal of Haematology
WOS: 000478608100031
PubMed ID: 31148155
Transfusion-dependent thalassaemia (TDT) requires red blood cell concentrates (RBCC) to prevent complications of anaemia, but carries risk of infection. Pathogen reduction of RBCC offers potential to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5e18671e856b16584bde676b5859c0e
https://doi.org/10.1111/bjh.15963
Zobrazit plný text záznamu
4
Prevalence of natural and acquired antibodies to amustaline/glutathione pathogen reduced red blood cells
Autor: Erhard Seifried, Nina Mufti, Lisa Becker, Richard J. Benjamin, Anne North, Veronika Brixner, Melissa von Goetz, Christof Geisen, Laurence Corash
Background The INTERCEPT™ Blood System for Red Blood Cells (RBCs) utilizes amustaline (S-303) and glutathione (GSH) to inactivate pathogens and leukocytes in transfused RBCs. Treatment-emergent low titer non-hemolytic antibodies to amustaline/GSH R
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c39365c72b1b3e12db1c33114df1e01b
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/56536
Zobrazit plný text záznamu
6
Antibodies to biotinylated red blood cells in adults and infants: improved detection, partial characterization, and dependence on red blood cell-biotin dose
Autor: Donald M. Mock, Robert M. Cohen, Demet Nalbant, Robert L. Schmidt, Anne North, Ronald G. Strauss, John A. Widness, Robert S. Franco, Christof Geisen, Jose A. Cancelas, Alexander P.J. Vlaar
Publikováno v: Transfusion. 57:1488-1496
Background Biotin-labeled red blood cells (BioRBCs) are used for in vivo kinetic studies. Because BioRBC dosing occasionally induces antibodies, a sensitive and specific anti-BioRBC detection assay is needed. Study design and methods Aims were to 1)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51572acd8923b4a5adef8893aa0b546b
https://doi.org/10.1111/trf.14075
Zobrazit plný text záznamu
7
Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study
Autor: J. L. Gottschall, Nina Mufti, Salvador Rico, Anna Erickson, Neeta Rugg, N. Huang, Laurence Corash, Jose A. Cancelas, Anne North, Sharon Graminske, M. A. Schott
Publikováno v: Vox Sanguinis. 112:210-218
Background and Objectives Pathogen reduction technology using amustaline (S-303) was developed to reduce the risk of transfusion-transmitted infection and adverse effects of residual leucocytes. In this study, the viability of red blood cells (RBCs)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5049322313c34ce9f723f019a3c9309e
https://doi.org/10.1111/vox.12500
Zobrazit plný text záznamu
9
Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process
Autor: Nina Mufti, Louis Herschel, P. Gayle Pratt, Anne Erickson, Anne North, William Reed, Jose A. Cancelas, D. Nicole Worsham, Alan Siegel, Laurence Corash, Meisa Propst, Larry J. Dumont, Claire D. Sherman, Neeta Rugg, Zbigniew M. Szczepiorkowski
Publikováno v: Transfusion. 51:2367-2376
BACKGROUND: Transfusion-transmitted infections and immunologic effects of viable residual lymphocytes remain a concern in red blood cell (RBC) transfusion. Pathogen reduction technologies for RBC components are under development to further improve tr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8d7f8d7e9ef2b14f3c97fa6031289f5
https://doi.org/10.1111/j.1537-2995.2011.03163.x
Zobrazit plný text záznamu
10
Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment
Autor: Laurence Corash, Anne North, Nina Mufti, Vic Ciaravino
Publikováno v: Transfusion. 51:2208-2218
BACKGROUND: A system has been developed to inactivate a wide spectrum of blood-borne pathogens in red blood cells (RBCs) before transfusion. The system utilizes S-303 to target nucleic acids of pathogens and white blood cells. The safety of pathogen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2c8a5c71b5033980f59ff75583e2ea2
https://doi.org/10.1111/j.1537-2995.2011.03132.x
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje